All together, these findings indicate that miR-155 restores the drug responsiveness of bortezomib-resistant MM cells in vitro, likely via proteasome inhibition, and that PSMβ5 silencing recapitulates the same phenotypic effects. The gene discussed is PSMB5; the disease is Miyoshi myopathy.